These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34728106)

  • 41. Quantitative B and T cell abnormalities in four patients presenting with mucormycosis and prior asymptomatic COVID-19 infection.
    Mandke C; Divekar R; Pradhan V; Arora S
    BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35944939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.
    Sen M; Honavar SG; Bansal R; Sengupta S; Rao R; Kim U; Sharma M; Sachdev M; Grover AK; Surve A; Budharapu A; Ramadhin AK; Tripathi AK; Gupta A; Bhargava A; Sahu A; Khairnar A; Kochar A; Madhavani A; Shrivastava AK; Desai AK; Paul A; Ayyar A; Bhatnagar A; Singhal A; Nikose AS; Bhargava A; Tenagi AL; Kamble A; Nariani A; Patel B; Kashyap B; Dhawan B; Vohra B; Mandke C; Thrishulamurthy C; Sambare C; Sarkar D; Mankad DS; Maheshwari D; Lalwani D; Kanani D; Patel D; Manjandavida FP; Godhani F; Agarwal GA; Ravulaparthi G; Shilpa GV; Deshpande G; Thakkar H; Shah H; Ojha HR; Jani H; Gontia J; Mishrikotkar JP; Likhari K; Prajapati K; Porwal K; Koka K; Dharawat KS; Ramamurthy LB; Bhattacharyya M; Saini M; Christy MC; Das M; Hada M; Panchal M; Pandharpurkar M; Ali MO; Porwal M; Gangashetappa N; Mehrotra N; Bijlani N; Gajendragadkar N; Nagarkar NM; Modi P; Rewri P; Sao P; Patil PS; Giri P; Kapadia P; Yadav P; Bhagat P; Parekh R; Dyaberi R; Chauhan RS; Kaur R; Duvesh RK; Murthy R; Dandu RV; Kathiara R; Beri R; Pandit R; Rani RH; Gupta R; Pherwani R; Sapkal R; Mehta R; Tadepalli S; Fatima S; Karmarkar S; Patil SS; Shah S; Shah S; Shah S; Dubey S; Gandhi S; Kanakpur S; Mohan S; Bhomaj S; Kerkar S; Jariwala S; Sahu S; Tara S; Maru SK; Jhavar S; Sharma S; Gupta S; Kumari S; Das S; Menon S; Burkule S; Nisar SP; Kaliaperumal S; Rao S; Pakrasi S; Rathod S; Biradar SG; Kumar S; Dutt S; Bansal S; Ravani SA; Lohiya S; Ali Rizvi SW; Gokhale T; Lahane TP; Vukkadala T; Grover T; Bhesaniya T; Chawla U; Singh U; Une VL; Nandedkar V; Subramaniam V; Eswaran V; Chaudhry VN; Rangarajan V; Dehane V; Sahasrabudhe VM; Sowjanya Y; Tupkary Y; Phadke Y;
    Indian J Ophthalmol; 2021 Jul; 69(7):1670-1692. PubMed ID: 34156034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors: An experience from a public hospital in India.
    Syed-Abdul S; Babu AS; Bellamkonda RS; Itumalla R; Acharyulu G; Krishnamurthy S; Ramana YVS; Mogilicharla N; Malwade S; Li YC
    J Infect; 2022 Mar; 84(3):351-354. PubMed ID: 34953910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 and Mucormycosis in India a Study on Implicated Risk Factors.
    Deepak P; Rao MR; Mandadi K
    J Assoc Physicians India; 2022 May; 70(5):11-12. PubMed ID: 35598140
    [No Abstract]   [Full Text] [Related]  

  • 46. Twitter sentiment analysis for COVID-19 associated mucormycosis.
    Singh M; Dhillon HK; Ichhpujani P; Iyengar S; Kaur R
    Indian J Ophthalmol; 2022 May; 70(5):1773-1779. PubMed ID: 35502071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric Mucormycosis and COVID-19.
    Yadav S
    J Contemp Dent Pract; 2021 Aug; 22(8):855. PubMed ID: 34753834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Online Registry of COVID-19-Associated Mucormycosis Cases, India, 2021.
    Arora S; Hemmige VS; Mandke C; Chansoria M; Rawat SK; Dravid A; Sethi Y; Medikeri G; Jariwala SP; Puius YA;
    Emerg Infect Dis; 2021; 27(11):2963-2965. PubMed ID: 34586056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mucormycosis Epidemic and Stroke in India During the COVID-19 Pandemic.
    Padma Srivastava MV; Vishnu VY; Pandit AK
    Stroke; 2021 Oct; 52(10):e622-e623. PubMed ID: 34525840
    [No Abstract]   [Full Text] [Related]  

  • 50. Two Uncommon Presentations of COVID-19-Associated Mucormycosis.
    Rathna R; D'Souza C; D'Silva C; Joseph JM; Varghese AK
    Cureus; 2022 Jan; 14(1):e21229. PubMed ID: 35186527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Past, Present and Future of COVID-19 Associated Mucormycosis: A Rapid Review.
    Sarfraz Z; Sarfraz A; Jaiswal V; Poudel S; Bano S; Hanif M; Singh Shrestha P; Sarfraz M; Michel G; Cherrez-Ojeda I
    J Prim Care Community Health; 2022; 13():21501319221099476. PubMed ID: 35587142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic.
    Bhanuprasad K; Manesh A; Devasagayam E; Varghese L; Cherian LM; Kurien R; Karthik R; Deodhar D; Vanjare H; Peter J; Michael JS; Thomas M; Samuel P; Varghese GM
    Int J Infect Dis; 2021 Oct; 111():267-270. PubMed ID: 34450284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucormycosis and Covid-19 : Risk Factors, Clinical Presentation and Outcome in a Tertiary Care Centre in North India.
    A GA; Ashraf H; HaiderMehdi HS
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucormycosis as SARS-CoV2 sequelae in kidney transplant recipients: a single-center experience from India.
    Meshram HS; Kute VB; Chauhan S; Dave R; Patel H; Banerjee S; Desai S; Kumar D; Navadiya V; Mishra V
    Int Urol Nephrol; 2022 Jul; 54(7):1693-1703. PubMed ID: 34792722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COVID-19 Associated Mucormycosis (CAM): A Single Hospital-Based Study.
    Vijapur MM; Kattimani V; Varsha VK; Girish HC; Kamat M; Ram B
    J Oral Maxillofac Pathol; 2022; 26(2):147-155. PubMed ID: 35968169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New-onset hyperglycaemia and prolonged systemic corticosteroids therapy in mild COVID-19 patients as major risk factors for invasive mucormycosis: a preliminary study.
    Khichar S; Samantaray S; Kumar D; Mobarsa V; Jain V; Sharma V; Soni K; Choudhury B; Goyal A; Shankar Meena D; Srinivasan S; Dutt N; Bhardwaj P; Agarwal A; Kumar Garg M; Misra S
    Curr Med Mycol; 2021 Sep; 7(3):22-28. PubMed ID: 35528622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
    Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
    J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.
    Samson R; Dharne M
    3 Biotech; 2022 Jan; 12(1):6. PubMed ID: 34900512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.
    Madhavan Y; Sai KV; Shanmugam DK; Manimaran A; Guruviah K; Mohanta YK; Venugopal DC; Mohanta TK; Sharma N; Muthupandian S
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806905
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.